Novavax (NVAX) Trading Up -1.9%

Shares of Novavax, Inc. (NASDAQ:NVAX) rose 1.9% during trading on Wednesday . The company traded as high as $2.10 and last traded at $2.04. Approximately 4,449,116 shares were traded during trading, a decline of 69% from the average daily volume of 14,429,632 shares. The stock had previously closed at $2.08.

NVAX has been the topic of several recent research reports. Citigroup upgraded Novavax from a “neutral” rating to a “buy” rating and set a $2.00 price target on the stock in a research report on Tuesday, October 31st. Zacks Investment Research cut Novavax from a “hold” rating to a “sell” rating in a research report on Thursday, November 16th. BidaskClub upgraded Novavax from a “hold” rating to a “buy” rating in a research report on Saturday, December 30th. S&P Equity Research dropped their price target on Novavax from $1.81 to $1.35 in a research report on Wednesday, January 10th. Finally, Cantor Fitzgerald restated a “hold” rating and issued a $2.00 price target on shares of Novavax in a research report on Wednesday, November 8th. Two research analysts have rated the stock with a sell rating, five have given a hold rating and three have given a buy rating to the company. Novavax presently has a consensus rating of “Hold” and a consensus target price of $2.64.

The stock has a market cap of $675.55, a PE ratio of -2.94 and a beta of 2.68. The company has a debt-to-equity ratio of -4.28, a quick ratio of 3.31 and a current ratio of 3.31.

Novavax (NASDAQ:NVAX) last announced its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.16) by $0.01. The business had revenue of $8.35 million during the quarter, compared to analysts’ expectations of $6.42 million. During the same period in the prior year, the firm posted ($0.24) EPS. Novavax’s revenue for the quarter was up 158.5% compared to the same quarter last year. equities analysts forecast that Novavax, Inc. will post -0.62 earnings per share for the current year.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Swiss National Bank boosted its holdings in Novavax by 21.0% in the 4th quarter. Swiss National Bank now owns 540,850 shares of the biopharmaceutical company’s stock valued at $671,000 after purchasing an additional 93,800 shares in the last quarter. Teacher Retirement System of Texas boosted its holdings in Novavax by 349.8% in the 4th quarter. Teacher Retirement System of Texas now owns 99,952 shares of the biopharmaceutical company’s stock valued at $124,000 after purchasing an additional 77,733 shares in the last quarter. Aperio Group LLC boosted its holdings in Novavax by 121.1% in the 4th quarter. Aperio Group LLC now owns 115,323 shares of the biopharmaceutical company’s stock valued at $143,000 after purchasing an additional 63,155 shares in the last quarter. Fisher Asset Management LLC purchased a new stake in Novavax in the 4th quarter valued at approximately $179,000. Finally, Schwab Charles Investment Management Inc. boosted its holdings in Novavax by 17.8% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 1,443,013 shares of the biopharmaceutical company’s stock valued at $1,790,000 after purchasing an additional 217,995 shares in the last quarter. 35.71% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This piece of content was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at https://sportsperspectives.com/2018/02/09/novavax-nvax-trading-up-1-9.html.

Novavax Company Profile

Novavax, Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases.

Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply